Activin II型受体阻断治疗COPD肌肉消耗的随机试验
该随机试验纳入67例COPD伴骨骼肌量减少患者,分别接受bimagrumab 30 mg/kg静脉注射或安慰剂(第0、8周),共24周。bimagrumab组大腿肌肉体积自第4周起显著增加并持续至第24周,但6分钟步行距离未显著改善。治疗相关不良事件多为轻度。
要点
- bimagrumab可安全增加COPD患者骨骼肌量
- 肌肉量增加未转化为运动功能改善
- 不良事件以肌肉相关症状、腹泻和痤疮为主,多为轻度
核心结论
- 阻断activin II型受体可安全增加COPD伴低肌肉量患者的骨骼肌量,但未改善功能能力。
研究设计与样本
- 随机试验纳入67例COPD患者(平均FEV1 1.05 L,占预计值41.6%;年龄40-80岁;BMI<20 kg/m2或四肢骨骼肌量指数男性≤7.25、女性≤5.67 kg/m2)。
- 患者随机接受bimagrumab 30 mg/kg静脉注射(n=33)或安慰剂(n=34),第0周和第8周给药,观察24周。
- 主要终点为大腿肌肉体积变化,次要终点包括6分钟步行距离、安全性和耐受性。
主要发现
- bimagrumab组大腿肌肉体积第4周增加5.9%(SD 3.4%),安慰剂组0.0%(3.3%),P<0.001。
- 第8周bimagrumab组增加7.0%(3.7%),安慰剂组-0.7%(2.8%),P<0.001。
- 第16周bimagrumab组增加7.8%(5.1%),安慰剂组-0.9%(4.5%),P<0.001。
- 第24周bimagrumab组增加5.0%(4.9%),安慰剂组-1.3%(4.3%),P<0.001。
- 24周内两组6分钟步行距离均未显著增加。
临床怎么用
- bimagrumab可考虑用于增加COPD伴肌肉消耗患者的骨骼肌量,但不应期望改善运动功能。
- 治疗期间需监测肌肉相关症状、腹泻和痤疮等不良事件。
局限性
- 研究未显示功能改善,临床获益需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators. OBJECTIVES: To assess the effects of bimagrumab on skeletal muscle mass and function in patients with chronic obstructive pulmonary disease (COPD) and reduced skeletal muscle mass. METHODS: Sixty-seven patients with COPD (mean FEV1, 1.05 L [41.6% predicted]; aged 40-80 yr; body mass index < 20 kg/m2 or appendicular skeletal muscle mass index ≤ 7.25 [men] and ≤ 5.67 [women] kg/m2), received two doses of either bimagrumab 30 mg/kg intravenously (n = 33) or placebo (n = 34) (Weeks 0 and 8) over 24 weeks. MEASUREMENTS AND MAIN RESULTS: We assessed changes in thigh muscle volume (cubic centimeters) as the primary endpoint along with 6-minute-walk distance (meters), safety, and tolerability. Fifty-five (82.1%) patients completed the study. Thigh muscle volume increased by Week 4 and remained increased at Week 24 in bimagrumab-treated patients, whereas no changes were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P < 0.001; Week 8: +7.0% [3.7%] vs. -0.7% [2.8%], P < 0.001; Week 16: +7.8% [5.1%] vs. -0.9% [4.5%], P < 0.001; Week 24: +5.0% [4.9%] vs. -1.3% [4.3%], P < 0.001). Over 24 weeks, 6-minute-walk distance did not increase significantly in either group. Adverse events in the bimagrumab group included muscle-related symptoms, diarrhea, and acne, most of which were mild in severity. CONCLUSIONS: Blocking the action of negative muscle regulators through the activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass. Clinical trial registered with www.clinicaltrials.gov (NCT01669174).
引用
- Polkey MI, Praestgaard J, Berwick A, et al. Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. Am J Respir Crit Care Med. 2019. PMID: 30095981. doi:10.1164/rccm.201802-0286OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。